Viewing
News|Articles|November 17, 2026

Johnson & Johnson to acquire Ollin Biosciences in deal worth up to $3.3 billion

The agreement brings J&J a next-generation bispecific antibody that outpaced faricimab on early anatomic measures in the phase 1b JADE trial, with Blackstone Life Sciences committing $750 million to fund phase 3 development.

Johnson & Johnson has signed a definitive agreement to acquire Ollin Biosciences, the Austin, Texas–based clinical-stage biotech developing OLN324, an investigational VEGF/Ang2 bispecific antibody for wAMD and DME.1 Under the terms of the deal, J&J will pay $2.2 billion upfront, with Ollin shareholders eligible for up to approximately $1.125 billion in further regulatory and commercial milestones, bringing the total potential value to roughly $3.3 billion.1,2

The transaction is expected to close before the end of 2026, subject to regulatory approvals and customary closing conditions.1

Deal terms and phase 3 funding

Alongside the acquisition, J&J has entered into an agreement with Blackstone Life Sciences that becomes effective only if the deal closes. Under that arrangement, Blackstone will pay J&J a total of $750 million over several years to fully fund phase 3 development of OLN324. In return, Blackstone is eligible for certain regulatory and sales milestone payments and single-digit royalties.1

Kip Connor, vice president and Ophthalmology Disease Area Stronghold Leader at J&J, said OLN324 "selectively targets 2 important drivers of retinal disease," adding that the data to date suggest a "potentially transformative clinical profile" that could give patients more time between treatments.1

What OLN324 brings to the table

OLN324, discovered by and developed in collaboration with Innovent Biologics, shares its dual-pathway mechanism with faricimab (Vabysmo; Genentech), the first VEGF/Ang2 inhibitor approved for wAMD and DME.3,6 Ollin has differentiated the molecule on 3 fronts: higher Ang2 potency relative to faricimab, higher molar dosing relative to faricimab and aflibercept, and a smaller "minibody" protein format that the company says could enable improved control of retinal fluid.1,6

According to the releases, wAMD and DME together affect more than 40 million people worldwide and remain leading causes of vision loss.1,2 Ollin co-founder and executive chairman Paul Berns, a managing director at ARCH Venture Partners, pointed to a retina therapeutics market estimated at $15 billion worldwide.2

The JADE evidence base

The clinical rationale for the acquisition rests largely on JADE, a randomized, US-based phase 1b proof-of-concept study that enrolled 164 patients with DME or wAMD. Participants received 3 monthly intravitreal injections of OLN324 2 mg, OLN324 4 mg, or faricimab 6 mg, followed by a 12-week observation period with retreatment permitted under prespecified criteria.3,4

As Ophthalmology Times reported when topline results were released in January, nearly 90% of OLN324 4 mg–treated patients with DME achieved absence of DME at week 12, compared with 57% of those treated with faricimab.3 Data presented at the 44th Annual Meeting of the American Society of Retina Specialists in Montréal showed that anatomic separation emerged as early as week 1 in the 83-patient DME cohort, with least squares mean central subfield thickness reductions of 76.3 µm and 79.0 µm for OLN324 2 mg and 4 mg, respectively, vs 44.8 µm for faricimab.5

Final week-20 data showed numerically greater visual acuity gains with OLN324 in both diseases. In DME, 93% of OLN324-treated patients completed the 12-week treatment-free period without retreatment vs 89% with faricimab. In wAMD, retinal thickness reductions were similar between groups, with a mean best-corrected visual acuity difference of +2.2 letters numerically favoring OLN324 and retreatment-free rates of 82% vs 81%.4

On safety, no cases of intraocular inflammation, retinal vasculitis, or occlusive retinal vasculitis were reported in the OLN324 arms through week 20; 1 case of intraocular inflammation occurred in the faricimab group.4

From launch to acquisition in just over a year

The deal caps a rapid trajectory for Ollin. Founded in 2023, the company formally launched in September 2025 with $100 million in initial financing led by ARCH Venture Partners, Mubadala Capital, and Monograph Capital.7 In June 2026, following the JADE readout, an end-of-phase 2 meeting with the FDA, and scientific advice from the European Medicines Agency, Ollin closed an oversubscribed $330 million Series B co-led by TCGX and ARCH to support global phase 3 trials in DME and wAMD.6

"We're encouraged by what the future could hold," said Jason S. Ehrlich, MD, PhD, Ollin's chief executive officer and co-founder.2 Berns added, "We're confident that the potential acquisition of Ollin will enable OLN324 to reach as many patients as possible."2

For J&J, the acquisition marks a significant push into retinal therapeutics for a company whose ophthalmology footprint has been built predominantly in surgical vision and contact lenses; earlier this year, for example, the FDA approved its TECNIS PureSee extended-depth-of-focus IOL.8 J&J framed the deal as strengthening its leadership in ophthalmology and its broader goal to preserve, restore, and enhance vision.1

What comes next

Phase 3 development is now the critical test. Ollin has registered GOBI (NCT07842016), a phase 3 study comparing OLN324 with aflibercept in an estimated 450 adults with DME.9 Whether the early anatomic advantage seen in JADE translates into clinically meaningful gains in vision and durability against established standards of care, at scale and over longer follow-up, will determine whether OLN324 can carve out a place in an increasingly competitive anti-VEGF landscape.

References
  1. Johnson & Johnson to acquire Ollin Biosciences and late-stage bispecific antibody with best-in-class potential in ophthalmology. News release. Johnson & Johnson. November 16, 2026. Accessed November 16, 2026. https://www.businesswire.com/news/home/20261116907414/en/
  2. Ollin Biosciences and its next-generation medicines for patients with vision-threatening eye diseases to be acquired by Johnson & Johnson. News release. Ollin Biosciences. November 15, 2026. Accessed November 16, 2026. https://www.businesswire.com/news/home/20261115727763/en/
  3. Harp MD. Ollin Biosciences reports positive head-to-head phase 1b data for OLN324 vs faricimab. Ophthalmology Times. January 9, 2026. Accessed November 16, 2026. https://www.ophthalmologytimes.com/view/ollin-biosciences-reports-positive-head-to-head-phase-1b-data-for-oln324-vs-faricimab
  4. OLN324 shows comparable vision gains, potential durability advantage vs faricimab in phase 1b wAMD, DME study. Ophthalmology Times. March 30, 2026. Accessed November 16, 2026. https://www.ophthalmologytimes.com/view/oln324-shows-comparable-vision-gains-potential-durability-advantage-vs-faricimab-in-phase-1b-wamd-dme-study
  5. Sheth VS, Gambuzza L. ASRS 2026: JADE trial shows OLN324 achieves faster retinal drying and durable response over faricimab in DME. Ophthalmology Times. July 16, 2026. Accessed November 16, 2026. https://www.ophthalmologytimes.com/view/asrs-2026-jade-trial-oln324-achieves-faster-retinal-drying-durable-response-over-faricimab-dme
  6. Ollin Biosciences announces oversubscribed $330 million Series B financing to advance global phase 3 development of OLN324 in DME and wet AMD. News release. Ollin Biosciences. June 23, 2026. Accessed November 16, 2026. https://www.businesswire.com/news/home/20260623783799/en/
  7. Ollin Biosciences announces its official launch. Ophthalmology Times. Accessed November 16, 2026. https://www.ophthalmologytimes.com/view/ollin-biosciences-announces-its-official-launch
  8. Charters L. Q1 2026 happenings in ophthalmology: major highlights. Ophthalmology Times. March 27, 2026. Accessed November 16, 2026. https://www.ophthalmologytimes.com/view/q1-2026-happenings-in-ophthalmology-major-highlights
  9. Phase 3 study of intravitreal OLN324 in adults with diabetic macular edema (DME) (GOBI). ClinicalTrials.gov identifier: NCT07842016. Accessed November 16, 2026. https://clinicaltrials.gov/study/NCT07842016

Related to this article